New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline

NEXT STORY
New To The Street / Newsmax TV Announces 8 Interviews For This Weeks’ Broadcast, Sunday, June 20, 2021, Hour Slot 10-11 AM ET
PREV STORY
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Subscribe to PM360
Follow Us

Experts on Call

Get in touch with PM360 Experts On Call

New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline

NEXT STORY
New To The Street / Newsmax TV Announces 8 Interviews For This Weeks’ Broadcast, Sunday, June 20, 2021, Hour Slot 10-11 AM ET
PREV STORY
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Subscribe to PM360
Follow Us

Experts on Call

Get in touch with PM360 Experts On Call

Ads

You May Also Like

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding March 5, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of ...

author_avatar
NASDAQ Market News

Delcath Announces Commercial Licensing Agreement for CHEMOSAT®

7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe Upfront and ...

author_avatar
NASDAQ Market News

pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA

WATERTOWN, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader ...

author_avatar
NASDAQ Market News